women who are BRCA -positive. 6 Retrospective studies of BRCA carriers indicate that adjuvant tamoxifen 7 and risk-reduction mastectomy can significantly reduce the risk for new primary breast cancer, up to 50% and 90%, respectively. 8 Risk
Search Results
Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership
Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel
Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I–III Breast Cancer
Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen
subtypes are a key determinant. Clinical trials have demonstrated that patients with HR+ (ER+ and/or PR+) breast cancer benefit from tamoxifen, those with HR– (ER– and PR–) benefit from adjuvant chemotherapy, and those with HER2+ disease benefit from
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer
Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu
cancer treatment utilization. A prior study suggested that RCT results significantly increased anastrozole prescription for postmenopausal women with hormone receptor–positive early breast cancer. 4 Another study showed an increase in tamoxifen use after
Receipt of Guideline-Concordant Care Among Older Women With Stage I–III Breast Cancer: A Population-Based Study
Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long
. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977 . 11. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles Cleeland, David Craig, Ellin Gafford, Heather Greenlee, Eric Hansen, Arif H. Kamal, Mihir M. Kamdar, Susan LeGrand, Sean Mackey, M. Rachel McDowell, Natalie Moryl, Lisle M. Nabell, Suzanne Nesbit, BCPS, Nina O’Connor, Michael W. Rabow, Elizabeth Rickerson, Rebecca Shatsky, Jill Sindt, Susan G. Urba, Jeanie M. Youngwerth, Lydia J. Hammond, and Lisa A. Gurski
attention to serotonergic medications (eg, SSRIs) due to risk of serotonin syndrome. Several antidepressants are known inhibitors of hepatic drug metabolism via inhibition of cytochrome P450 enzymes, especially CYP2D6. Tamoxifen is an estrogen receptor
Venous Thromboembolic Disease
Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma
undergoing chemotherapy. Increased VTE risk was shown to be associated with the use of exogenous hormonal compounds, such as selective estrogen receptor modulators (eg, tamoxifen, raloxifene), for the prevention and treatment of certain estrogen receptor
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen
erythropoietic stimulating agents (ESAs). Exogenous hormonal compounds, such as selective estrogen receptor modulators (eg, tamoxifen, raloxifene for breast cancer) can lead to increased VTE risk. 92 – 96 Diethylstilbestrol phosphate used in combination with
Epithelial Ovarian Cancer
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
a clinical relapse is 2 to 6 months. A lack of consensus exists regarding the timing of recurrence therapy for patients who have undergone previous chemotherapy. Because tamoxifen and other hormonally active agents have a defined response rate in
Solid Malignancies in Individuals With Down Syndrome: A Case Presentation and Literature Review
Scott V. Bratman, Kathleen C. Horst, Robert W. Carlson, and Daniel S. Kapp
treatment break was required to allow for healing after the patient developed moist desquamation on the chest wall. Tamoxifen was initiated after radiotherapy and continues at the time of writing. 7 At 57 months after surgery, the patient has remained
Adolescent and Young Adult Oncology, Version 2.2014
Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead, and Hema Sundar
history of breast cancer, although for women treated with tamoxifen, levonorgestrel-containing intrauterine system (IUS) may be preferable because it has been shown to reduce tamoxifen-induced endometrial changes without increasing the risk of breast
